Purpose: This study will collect patient demographic, oncology history, and physician reported outcome information following the initial round of chemotherapy received after a commercial ChemoFx® Final Report for the generation of hypotheses of potential patient cohorts for further sub-studies.
Mesothelioma
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS)
Purpose: Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.
- Arm 1: Standard Chemotherapy
- Drug: Standard Chemotherapy (Pemetrexed and Cisplatin)
-
- Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
- Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
- Arm 2: Standard Chemotherapy + bevacizumab (Avastin)
- Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
-
- Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
- Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
- Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Dasatinib in Resectable Malignant Pleural Mesothelioma
- Primary Objectives:
- The primary objective of this novel phase I trial will be the level of biomarker modulation of p-Src Tyr 419 by induction dasatinib therapy in patients with resectable malignant pleural mesothelioma.
- Secondary Objectives:
- Secondary objectives include overall and progression-free survival, tumor radiographic and pathologic response, and safety-toxicity profiles. Exploratory analyses will include additional biomarker evaluation in pre- and post-treatment tumor specimens, and serum/platelet/pleural effusion biomarker modulation.
- Arms: Dasatinib: Experimental
- 70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy (NAC-PNP)
Purpose: In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.
- Arm 1: Active Comparator
-
- Drug: N-Acetylcysteine.
- Intervention:
N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg. - Other Name: Fluimucil
- Arm 2: Placebo Comparator
-
- Drug: Placebo.
- Intervention: Placebo once every 3 weeks intravenous saline fluid.
- Other Name: Placebo
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Rationale: Immunotoxins can find tumor cells and kill them without harming normal cells. Drugs used in chemotherapy, such as pemetrexed and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with immunotoxin therapy may kill more malignant mesothelioma cells.
Purpose: This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Rationale: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Purpose: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients with malignant pleural mesothelioma.
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
Purpose: The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.
Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases From Cancers of Non-Thoracic Origin
Rationale: Collecting and storing samples of tissue, blood, and urine from patients with cancer to study in the laboratory may help the study of cancer. It may also help doctors identify patients who are eligible for clinical trials.
Purpose: This study is collecting and examining tissue, blood, and urine samples from patients with non-small cell lung cancer, esophageal cancer, malignant pleural mesothelioma, mediastinal or chest wall neoplasms, or lung metastases from cancers of non-thoracic origin.
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Purpose: The purpose of this trial is to collect blood serum from cancer patients with tumors at different disease sites (such as pancreas, head and neck, and breast) prior to and at subsequent points following anti-cancer therapy to discover novel serum markers of response.
AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Rationale: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Purpose: This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.
Skip to content